Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group.

Neurology. 2012 Apr 17;78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.

2.

Venlafaxine extended-release: a review of its use in the management of major depression.

Wellington K, Perry CM.

CNS Drugs. 2001;15(8):643-69. Review.

PMID:
11524036
3.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
4.

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG.

J Psychopharmacol. 2010 Aug;24(8):1209-16. doi: 10.1177/0269881109106953. Epub 2009 Nov 25.

PMID:
19939870
5.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
6.

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.

JAMA. 2000 Jun 21;283(23):3082-8.

PMID:
10865302
7.
8.

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.

Shelton C, Entsuah R, Padmanabhan SK, Vinall PE.

Int Clin Psychopharmacol. 2005 Jul;20(4):233-8.

PMID:
15933485
10.
12.

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Kennedy SH, Andersen HF, Lam RW.

J Psychiatry Neurosci. 2006 Mar;31(2):122-31. Erratum in: J Psychiatry Neurosci. 2006 Jul;31(4):228.

13.

A controlled trial of antidepressants in patients with Parkinson disease and depression.

Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A.

Neurology. 2009 Mar 10;72(10):886-92. doi: 10.1212/01.wnl.0000336340.89821.b3. Epub 2008 Dec 17.

14.

A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y.

Psychopharmacology (Berl). 2007 Oct;194(2):233-42. Epub 2007 Jun 23. Erratum in: Psychopharmacology (Berl). 2008 Feb;196(2):339. Zhang, Ying [added].

PMID:
17589833
16.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
17.

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.

Stahl SM, Entsuah R, Rudolph RL.

Biol Psychiatry. 2002 Dec 15;52(12):1166-74.

PMID:
12488062
18.

Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.

Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I.

JAMA. 1998 Jan 28;279(4):287-91.

PMID:
9450712
20.

Efficacy of controlled-release paroxetine in the treatment of late-life depression.

Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD.

J Clin Psychiatry. 2003 Sep;64(9):1065-74.

PMID:
14628982

Supplemental Content

Support Center